Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | ACE | P12821 | 9/20 | 0.67 |
| ▸ | MME | P08473 | 7/20 | 0.67 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12863002 | 1.00 | NPSR1 (0.69) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL244885 | 1.00 | NPSR1 (0.69) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL683352 | 0.89 | NPSR1 (0.55) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL684246 | 0.89 | NPSR1 (0.55) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL30587429 | 0.87 | ACE (0.59) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL2550703 | 0.87 | FOLH1 (0.61) | NPSR1ACEMMEACE2NAALAD2 | |
| SCHEMBL2550705 | 0.87 | FOLH1 (0.61) | NPSR1ACEMMEACE2NAALAD2 | |
| SCHEMBL10408617 | 0.87 | ACE (0.68) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL12862963 | 0.87 | NPSR1 (0.54) | NPSR1ACEMMEACE2MMP1 | |
| SCHEMBL13886186 | 0.86 | NPSR1 (0.54) | NPSR1ACEMMEACE2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | claimed |
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | disclosed |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | EPIGEN BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| CN-106220635-B | The dihydro diaza * and carbazole ketone at the condensed Fourth Ring or five rings as PARP inhibitor | 百济神州有限公司 | 2019-03-08 | — | — | CN | disclosed |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9988492-B2 | Methods for post-fabrication functionalization of poly(ester ureas) | THE UNIVERSITY OF AKRON (US) | 2018-06-05 | — | — | US | disclosed |
| CN-106220635-A | As the Fourth Ring condensed of PARP inhibitor or the dihydro diaza * at five rings carbazole ketone | 百济神州有限公司 | 2016-12-14 | — | — | CN | disclosed |
| CN-103703004-B | Fused tetracyclic or pentacyclic dihydrodiaza-carbazolones as PARP inhibitors | 百济神州有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| CN-103703004-A | Fused tetracyclic or pentacyclic dihydrodiaza-carbazolones as PARP inhibitors | BEIGENE LTD | 2014-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135767-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR2, LPAR4 | NPSR1 293/4885ACE 3633/4885MME 1808/4885 |
| US-10000459-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | NPSR1 171/4885ACE 4412/4885MME 2668/4885 |
| US-20160024031-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR4, LPAR3 | NPSR1 182/4885ACE 4373/4885MME 2653/4885 |
| US-20200181099-A1 | Heterocyclic Compounds Useful In The Treatment Of Disease | LPAR1, LPAR4, LPAR3 | NPSR1 171/4885ACE 4412/4885MME 2668/4885 |
| US-10570103-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR2, LPAR4 | NPSR1 293/4885ACE 3633/4885MME 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.